Opthea Limited (OPTEY) - Total Assets
Based on the latest financial reports, Opthea Limited (OPTEY) holds total assets worth $145.77 Million USD as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore OPTEY debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Opthea Limited - Total Assets Trend (2022–2025)
This chart illustrates how Opthea Limited's total assets have evolved over time, based on quarterly financial data. See Opthea Limited shareholders equity for net asset value and shareholders' equity analysis.
Opthea Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Opthea Limited's total assets of $145.77 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Opthea Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Opthea Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Opthea Limited's current assets represent 100.0% of total assets in 2025, an increase from 99.8% in 2022.
- Cash Position: Cash and equivalents constituted 85.3% of total assets in 2025, up from 74.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Opthea Limited Competitors by Total Assets
Key competitors of Opthea Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Opthea Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 2.94 | - |
| Quick Ratio | 1.57 | 2.94 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $52.38 Million | $124.14 Million | - |
Opthea Limited - Advanced Valuation Insights
This section examines the relationship between Opthea Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.31 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -69.9% |
| Total Assets | $56.80 Million |
| Market Capitalization | $2.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Opthea Limited's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Opthea Limited's assets decreased by 69.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Opthea Limited (2022–2025)
The table below shows the annual total assets of Opthea Limited from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $56.80 Million | -69.91% |
| 2024-06-30 | $188.79 Million | +91.39% |
| 2023-06-30 | $98.64 Million | +64.27% |
| 2022-06-30 | $60.05 Million | -- |
About Opthea Limited
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more